Table I.
Baseline clinical characteristics of participants with detectable and undetectable cTnT
| Undetectable cTnTb 0.01 ng/mL (n = 929) | Detectable cTnT =0.01 ng/mL (n = 58) | p | |
|---|---|---|---|
| Demographics | |||
| Age, y (mean ± SD) | 66 ± 11 | 70 ± 12 | .01 |
| Male sex, n (%) | 753/929 (81.0) | 51/58 (87.9) | .19 |
| Body mass index (mean ± SD) | 29 ± 5 | 27 ± 5 | .03 |
| White, n (%) | 566/928 (61.0) | 29/58 (50.0) | .10 |
| CHD risk factors | |||
| Hypertension, n (%) | 649/927 (70%) | 46/58 (79.3%) | .13 |
| Systolic blood pressure, mm Hg (mean ± SD) | 133 ± 21 | 138 ± 22 | .09 |
| Diastolic blood pressure, mm Hg (mean ± SD) | 75 ± 11 | 75 ± 12 | .73 |
| Hypercholesterolemia, n (%) | 617/923 (66.8) | 37/58 (63.8) | .70 |
| Diabetes, n (%) | 227/927 (24.5) | 32/58 (55.2) | <.001 |
| Current smoking, n (%) | 188/927 (20.3) | 8/58 (13.8) | .23 |
| Medication use | |||
| β-Blocker, n (%) | 534 (57.5) | 33 (56.9) | .93 |
| ACEI/ARB, n (%) | 468 (50.4) | 37 (63.8) | .05 |
| Aspirin, n (%) | 723 (77.8) | 39 (67.2) | .06 |
| Statins, n (%) | 595 (64.1) | 38 (65.5) | .82 |
| Previous cardiovascular events | |||
| MI, n (%) | 493/924 (53.4) | 34/57 (59.6) | .36 |
| Stroke, n (%) | 127/926 (13.7) | 13/58 (22.4) | .07 |
| Revascularization, n (%) | 543/927 (58.6) | 3/58 (60.3) | .79 |
| Angina frequency, one or more angina a week, n (%) | 170/927 (18.4) | 9/58 (15.5) | .35 |
| Heart failure, n (%) | 152 (16.5) | 21 (36.2) | <.001 |
| Laboratory tests | |||
| NT-proBNP, pg/mL (median ± IQR) | 161 ± 324 | 1098 ± 2407 | <.001 |
| CRP, mg/dL (median ± IQR) | 2.1 ± 3.9 | 3.1 ± 7.0 | .002 |
| Serum creatinine, mg/dL (mean ± SD) | 1.07 ± 0.34 | 2.30 ± 0.95 | <.001 |
| ECGs | |||
| Pathologic Q waves on ECG | 172/913 (18.8) | 14/57 (24.6) | .29 |
| Resting heart rate (mean ± SD) | 68 ± 13 | 68 ± 12 | .72 |
CHD, coronary heart disease; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; IQR, interquartile range.